An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A big review of existing studies found that semaglutide, a drug you've probably heard of from names like Ozempic or Wegovy, leads to substantial weight loss — on average about 14–17% of body weight. The headline also notes an important follow-up: people tend to regain weight after they stop taking it. So the good news is the drug works while people are on it; the less-good news is the benefit often fades when it’s stopped. Semaglutide is a man-made version of a natural hormone that your gut releases after eating. That hormone sends signals to your brain that help you feel full and also slows how fast your stomach empties. The drug mimics those signals more strongly and for longer than the natural hormone. In simple terms, it helps reduce appetite and makes you feel satisfied with less food. The review pooled results from multiple clinical trials — not a single new experiment — to see the overall effect across many people. Those trials are mostly controlled studies with people who were overweight or had obesity. Across the data, average weight loss landed in the mid-teens percentage-wise, which is larger than older weight-loss drugs typically achieved. But the review also found that when people stop taking semaglutide, much of the lost weight tends to come back. The report doesn’t mean every person will lose that exact amount or regain it, but it shows a common pattern in the studies. Why this matters is practical: for people struggling with obesity or weight-related health problems, semaglutide offers a much stronger, evidence-backed option than many older medications or diet attempts. That can lead to improvements in conditions like high blood pressure, diabetes risk, and mobility in many patients. It also reframes how we think about obesity treatment — as something that might need ongoing medical management rather than a one-time cure. There are important limits and risks to keep in mind. These findings come from clinical trials with specific groups, so results can vary in the real world. Side effects reported in trials include nausea, stomach issues, and other digestive complaints; rare but more serious risks have been described elsewhere and need medical oversight. The weight regain after stopping raises questions about long-term plans: who should stay on the drug indefinitely, and what are the costs and safety implications of long-term use? Semaglutide is a prescription medicine and should be used under a clinician’s guidance. Bottom line: semaglutide produces sizable weight loss for many people while they take it, but the benefits often decline after stopping, so it’s best viewed as a powerful tool that requires medical supervision and long-term strategy.
Source: Bioengineer.org